By Helgi Library - May 22, 2023
Zur Rose employed 2,283 employees in 2022, up 7.13% compared to the previous year. Historically, between 2010 and 2022,...
By Helgi Library - May 22, 2023
Zur Rose made a net profit of CHF -171 mil with revenues of CHF 1,608 mil in 2022, up by 24.2% and down by 6.77%, r...
By Helgi Library - May 22, 2023
Zur Rose stock traded at CHF 27.1 per share at the end 2022 translating into a market capitalization of USD 298 mil. Since the en...
| Profit Statement |
| Balance Sheet |
| Ratios |
| Valuation |
Get all company financials in excel:
Get all company financials in excel:
By Helgi Library - May 22, 2023
Zur Rose made a net profit of CHF -171 mil with revenues of CHF 1,608 mil in 2022, up by 24.2% and down by 6.77%, respectively, compared to the previous year. This translates into a net margin of -10.6%. On the operating level, EBITDA reached CHF -77.7 mil,...
By Helgi Library - May 22, 2023
Zur Rose made a net profit of CHF -171 mil with revenues of CHF 1,608 mil in 2022, up by 24.2% and down by 6.77%, respectively, compared to the previous year. This translates into a net margin of -10.6%. Historically, between 2010 and 2022, the firm...
By Helgi Library - May 22, 2023
Zur Rose invested a total of CHF 58.7 mil in 2022, down 7.5% compared to the previous year. Historically, between 2010 - 2022, the company's investments stood at a high of CHF 63.5 mil in 2021 and a low of CHF 3.07 mil in 2011. As a p...
By Helgi Library - May 22, 2023
Zur Rose made a net profit of CHF -171 mil in 2022, up 24.2% compared to the previous year. Historically, between 2010 and 2022, the company's net profit reached a high of CHF 8.67 mil in 2011 and a low of CHF -226 mil in 2021. The result implies a return...
By Helgi Library - May 22, 2023
Zur Rose stock traded at CHF 27.1 per share at the end 2022 implying a market capitalization of USD 298 mil. Since the end of 2017, stock has appreciated by -78.1% implying an annual average growth of -26.2% In absolute terms, the value of the company fe...
By Helgi Library - May 22, 2023
Zur Rose stock traded at CHF 27.1 per share at the end 2022 translating into a market capitalization of USD 298 mil. Since the end of 2017, the stock has depreciated by 78.1% representing an annual average growth of -26.2%. At the end of 2022, the firm t...
By Helgi Library - May 22, 2023
Zur Rose's net debt stood at CHF 398 mil and accounted for 113% of equity at the end of 2022. The ratio is up 53.4 pp compared to the previous year. Historically, the firm’s net debt to equity reached a high of 113% in 2022 and a low of -32.2...
By Helgi Library - August 3, 2020
Zur Rose made a net profit of CHF -17.6 mil with revenues of CHF 344 mil in 4Q2019, down by 64.3% and up by 13.7%, respectively, compared to the previous year. This translates into a net margin of -5.13%. On the operating level, EBITDA reached CHF -5.69 m...
By Helgi Library - August 3, 2020
Zur Rose's operating cash flow stood at CHF -33.6 mil in 4Q2019, down 239% when compared to the previous year. Historically, between 1Q2009 - 4Q2019, the firm’s operating cash flow reached a high of CHF 5.23 mil in 3Q2012 and a low of CHF -33.6 mil ...
By Helgi Library - October 12, 2020
Zur Rose's total assets reached CHF 992 mil at the end of 4Q2019, up 36.5% compared to the previous year. Current assets amounted to CHF 428 mil, or 43.2% of total assets while cash stood at CHF 205 mil at the end of 4Q2019. ...
The Swiss Zur Rose Group is Europe’s largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. The Company also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany’s best-known pharmacy brand DocMorris. Zur Rose employs more than 1,800 people at sites in Switzerland, Germany, the Netherlands, Spain and France. The Company's activities are divided into two business segments: Zur Rose and DocMorris. The Zur Rose division includes wholesale business and provides drugs to medical doctors, health insurance companies, hospitals and healthcare companies, among others. The DocMorris division manages the mail-order business for drug retail. The Company operates in Switzerland, Germany and the Netherlands through a number of subsidiaries, such as Zur Rose Suisse AG, Zur Rose Pharma GmbH, BlueCare AG, DocMorris NV, Eurapon Pharmahandel GmbH and Vitalsana BV.
DocMorris has been growing its sales by 3.19% a year on average in the last 5 years. EBITDA has grown on average by 20.1% a year during that time to total of CHF 123 mil in 2030, or 6.86% of sales. That’s compared to 5.38% average margin seen in last five years.
The company netted CHF 37.6 mil in 2030 implying ROE of 19.7% and ROCE of 4.50%. Again, the average figures were 6.46% and 1.37%, respectively when looking at the previous 5 years.
DocMorris’s net debt amounted to CHF 196 mil at the end of 2030, or 93.3% of equity. When compared to EBITDA, net debt was 1.59x, down when compared to average of 2.41x seen in the last 5 years.
DocMorris stock traded at CHF 33.0 per share at the end of 2030 resulting in a market capitalization of USD 363 mil. Over the previous five years, stock price grew by 0% or 0% a year on average. The closing price put stock at a 12-month trailing EV/EBITDA of 4.28x and price to earnings (PE) of 8.80x as of 2030.
Helgi Library 
